Strides completes acquisition of Aspen in Australia

In May this year, Strides inked an agreement to acquire the generic pharmaceutical business in Australia and related assets from Aspen


The transaction is worth A$380 million

Bangalore-based Strides Arcolab has announced that it has completed acquisition of Aspen Pharmacare's generic pharmaceutical business and related assets in Australia.

The transaction is worth A$380 million(approx. $297 million).

"The transaction has now achieved closure on completion of closing conditions and statutory and regulatory approvals," Strides said in a statement.

"The acquired business will be integrated and consolidated with Strides effective September 1, 2015," the company added.

The business will operate under the Arrow Pharmaceuticals brand.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email